Editor's Corner

As I'm putting the finishing touches to this year's Fierce 15 -- to be announced at BIO on June 20 -- it's struck me how much extraordinary research work is under way in this country and around the world. It's unfortunate that for many in the public, the only news they see about the drug industry deals with some new report about a giant multinational whose biggest concern was protecting a market rather than patients. Smaller biotechs thrive and writhe on the data, and in many cases, they serve as a better model of corporate behavior than their much bigger pharma brethren.

We're in the final days leading up to our announcement of the Fierce 15 in Philadelphia. Be sure to register here if you haven't already. There promises to be quite a crowd. - John Carroll

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.